A detailed history of Jpmorgan Chase & CO transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9 shares of ANEB stock, worth $13. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9
Previous 10 10.0%
Holding current value
$13
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$1.77 - $3.08 $1 - $3
-1 Reduced 10.0%
9 $0
Q2 2024

Aug 12, 2024

BUY
$1.9 - $3.12 $1 - $3
1 Added 11.11%
10 $0
Q1 2024

May 10, 2024

BUY
$2.34 - $3.0 $21 - $27
9 New
9 $0
Q1 2023

May 11, 2023

BUY
$2.27 - $3.25 $36 - $52
16 New
16 $0

Others Institutions Holding ANEB

About Anebulo Pharmaceuticals, Inc.


  • Ticker ANEB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,633,200
  • Market Cap $37.4M
  • Description
  • Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...
More about ANEB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.